Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, et al.
Cureus (2023)
Open Access | Times Cited: 18

Showing 18 citing articles:

Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications
George J. Kontoghiorghes
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12928-12928
Open Access | Times Cited: 27
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency
George J. Kontoghiorghes
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4654-4654
Open Access | Times Cited: 8
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations
Jessica Tetterton-Kellner, Brian C. Jensen, Juliane Nguyen
Advanced Drug Delivery Reviews (2024) Vol. 211, pp. 115361-115361
Closed Access | Times Cited: 6
The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases
George J. Kontoghiorghes
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 1016-1016
Open Access | Times Cited: 12
Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies
Yingpu Sun, Lili Xiao, Linlin Chen, et al.
Cardiovascular Drugs and Therapy (2025)
Closed Access
Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats
Patricia Lorena Dulf, Camelia Alexandra Coadă, Adrian Florea, et al.
Antioxidants (2024) Vol. 13, Iss. 9, pp. 1068-1068
Open Access | Times Cited: 3
Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: Current approaches and future directions
Zeineb Al-Hasnawi, Haroon Hasan, Jaafar Mohammed Abdul Azeez, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 12, pp. 7212-7220
Open Access | Times Cited: 3
Evaluation of cardiotoxicity of anthracycline‐containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single‐center real‐world experience
Zeming Mo, Yaotiao Deng, Yiwen Bao, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 21709-21724
Open Access | Times Cited: 7
Construction of a Nomogram Risk Prediction Model for Acute Cardiotoxicity Associated with Anthracycline Drugs in Pediatric Hematological Tumors: a retrospective cohort study in China
Yanjun Zhou, Chunli Wang, Wei Chi
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs
George J. Kontoghiorghes
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16749-16749
Open Access | Times Cited: 6
Therapeutic potential of synthetic and natural iron chelators against ferroptosis
Nupura Manish Prabhune, Bilal Ameen, Sudharshan Prabhu
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 1
Abnormal Global Longitudinal Strain During Anthracycline Treatment Predicts Future Cardiotoxicity in Children
Megan Gunsaulus, Tarek Alsaied, Jean M. Tersak, et al.
Pediatric Cardiology (2023) Vol. 45, Iss. 8, pp. 1750-1758
Open Access | Times Cited: 3
Deciphering the Protective Effects of Carvacrol Against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo
Rini Retnosari, Muhamad Adib Abdul Ghani, Munirah Majed Alkharji, et al.
Research Square (Research Square) (2024)
Open Access
Carvacrol-Conjugated 3-Hydroxybenzoic Acids: Design, Synthesis, Cardioprotective Potential Against Doxorubicin-Induced Cardiotoxicity, and Admet Study
Rini Retnosari, Kentaro Oh‐hashi, Azizah Ugusman, et al.
(2024)
Closed Access
Carvacrol-conjugated 3-Hydroxybenzoic Acids: Design, Synthesis, cardioprotective potential against doxorubicin-induced Cardiotoxicity, and ADMET study
Rini Retnosari, Kentaro Oh‐hashi, Azizah Ugusman, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 113, pp. 129973-129973
Closed Access
The Protective Effects of Carvacrol Against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo
Rini Retnosari, Muhamad Adib Abdul Ghani, Munirah Majed Alkharji, et al.
Cardiovascular Toxicology (2024)
Closed Access
Serum Carnitine Concentrations and Cardiac Function in Pediatric, Adolescent and Young Adult Oncology Patients Receiving High-Dose Anthracyclines
Christine Lin, Hari K. Narayan, Erin Trovillion, et al.
The Journal of Pediatric Pharmacology and Therapeutics (2024) Vol. 29, Iss. 5, pp. 475-481
Closed Access
Page 1

Scroll to top